Fort Washington Investment Advisors’s Anika Therapeutics ANIK Stock Holding History

Fort Washington Investment Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-383,885	Closed	-$9.14M	–	389
2022 Q3	$9.14M	Sell	383,885 -109,453	-22%	-$2.52M	0.08%	196
2022 Q2	$11M	Buy	493,338 +107,810	+28%	+$2.41M	0.08%	188
2022 Q1	$9.68M	Buy	385,528 +37,840	+11%	+$1.15M	0.06%	204
2021 Q4	$12.5M	Buy	347,688 +31,810	+10%	+$1.27M	0.08%	193
2021 Q3	$13.4M	Buy	315,878 +4,804	+2%	+$198K	0.09%	153
2021 Q2	$13.5M	Buy	311,074 +55,191	+22%	+$2.35M	0.12%	125
2021 Q1	$10.4M	Buy	+255,883	New	+$9.71M	0.1%	188

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

Fort Washington Investment Advisors's ANIK Position: Q4 2022 in Review

Fort Washington Investment Advisors sold out of Anika Therapeutics (ANIK) in Q4 2022, closing a stake of 383,885 shares — an estimated $9.14M sold.

Fort Washington Investment Advisors first reported a position in ANIK in Q1 2021 and held it in 7 quarters. The position peaked at $13.5M in Q2 2021. 123 funds tracked by Wall St. Rank hold ANIK as of Q4 2022.

Fort Washington Investment Advisors reported no remaining Anika Therapeutics position as of Q4 2022 after selling out during the quarter.
Fort Washington Investment Advisors sold 383,885 Anika Therapeutics shares in Q4 2022, an estimated $9.14M.
Fort Washington Investment Advisors first reported a position in Anika Therapeutics in Q1 2021 and held it in 7 quarters.
Fort Washington Investment Advisors's Anika Therapeutics position peaked at $13.5M in Q2 2021.
123 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2022.

Based on Fort Washington Investment Advisors's 13F filing for Q4 2022, filed 30 Jan 2023.